Dr Aviral Singh
/content/dam/genesiscare/headshots/au-doctor-headshots/AU_Theranostics_Headshot_GA_Dr Aviral Singh.jpg

Dr Aviral Singh

Dr Aviral Singh
MD PGDipCard MSc FAfNM FRACP - Clinical Head of Theranostics and Nuclear Medicine

Theranostics may help to provide a comparatively safer, targeted, and individualised option for the management of cancer patients.

Languages spoken

English, Hindi, German, Russian



Murdoch (Oncology)
Murdoch (Oncology)
-32.067130818740424, 115.84572533810733

Clinical interests in Theranostics

Dr Aviral Singh gained his medical degree from Ukraine followed by clinical training in nuclear medicine, intensive care, and internal medicine from Ukraine, Germany, Australia, and United Kingdom.

Aviral is highly passionate about - Theranostics and gained extensive experience from the ENETS Centre of Excellence and EARL-accredited PET/CT Centre of Excellence at Zentralklinik Bad Berka, Germany.

Aviral achieved an M.Sc. in Nuclear Medicine from King’s College London, UK and is now pursuing a PhD from Maastricht University, Netherlands.

He is well-published with >45 peer reviewed scientific papers and >100 scientific abstracts presented at various international medical societies. His H-index is 28. Aviral is an Investigator in several multicentre clinical trials, previously including the NETTER-1 and COMPETE studies. He has participated in several first-in-human clinical translation studies using novel radiopharmaceuticals.

Aviral has received several international awards and recognition, including from SNMMI, ICRT, ESMO, and ENETS, and has been invited as a Faculty/Lecturer by international medical societies such as ANZSNM, ESMO, ENETS, COSA, WFNMB, and WARMTH.

He is a Member of the Governing Body of World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) and was its Treasurer and Member of the Executive Board from 2018 to 2023.

He is a Guest/Topics Editor for the Frontiers (Endocrinology and Nuclear Medicine) journals and is a regular peer reviewer for several reputed nuclear medicine journals.

Aviral is proficient in English, Russian, and German languages in addition to his native Hindi.

Professional memberships

  • ESMO

Research interests

Use of radiopharmaceuticals for molecular imaging with PET/CT and targeted therapy